Mosunetuzumab is effective and well tolerated in older patients with relapsed/refractory follicular lymphoma: Subgroup analysis of a phase I/II study
British Journal of Haematology · 2026-01 · 208 (1) · 149-158
DOI: 10.1111/bjh.70212 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift British Journal of Haematology, online erschienen am 18.11.2025. Verfasst von Swetha Kambhampati Thiruvengadam und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology/HCT, City of Hope National Medical Center, Duarte, California, USA. Hauptthemen laut MEDLINE: Lymphoma, Follicular, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Genentech, Inc., Genentech.
Abstract (Originalsprache)
A high unmet need for novel, safe and effective therapies exists among older patients with non‐Hodgkin lymphoma (NHL). We report safety and efficacy of mosunetuzumab in a subgroup analysis of a phase I/II study, which examined the prognostic impact of age in 218 patients with relapsed/refractory (R/R) B‐cell NHL (B‐NHL; ≥65 years, n = 102;
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology/HCT, City of Hope National Medical Center, Duarte, California, USA.
- Hematology and Blood and marrow Transplant, City of Hope Cancer Center, Atlanda, George, USA.
- Genentech, Inc., South San Francisco, California, USA.
- F. Hoffmann-La Roche Ltd, Shanghai, China.
ORCID-Profile: Alex F Herrera, Matthew Mei, Lihua E Budde
Förderung
- Genentech, Inc.
- Genentech
Zitieren
APA
Thiruvengadam, S. K., Popplewell, L. L., Herrera, A. F., Mei, M., Nikolaenko, L., Zuo, X., Yin, S., Zhou, M., Mun, Y., Wu, M., Wei, M. C., & Budde, L. E. (2026). Mosunetuzumab is effective and well tolerated in older patients with relapsed/refractory follicular lymphoma: Subgroup analysis of a phase I/II study. British Journal of Haematology, 208(1), 149-158. https://doi.org/10.1111/bjh.70212
Vancouver
Thiruvengadam SK, Popplewell LL, Herrera AF, Mei M, Nikolaenko L, Zuo X, et al. Mosunetuzumab is effective and well tolerated in older patients with relapsed/refractory follicular lymphoma: Subgroup analysis of a phase I/II study. British Journal of Haematology. 2026;208(1):149-158. doi:10.1111/bjh.70212
BibTeX
@article{Thiruvengadam2026,
author = {Thiruvengadam, Swetha Kambhampati and Popplewell, Leslie L and Herrera, Alex F and Mei, Matthew and Nikolaenko, Liana and Zuo, Xiaofang and Yin, Shen and Zhou, Mingzhu and Mun, Yong and Wu, Mei and Wei, Michael C and Budde, Lihua E},
title = {Mosunetuzumab is effective and well tolerated in older patients with relapsed/refractory follicular lymphoma: Subgroup analysis of a phase I/II study},
journal = {British Journal of Haematology},
year = {2026},
volume = {208},
number = {1},
pages = {149--158},
doi = {10.1111/bjh.70212}
}
EUVIMED